DK3003038T3 - 2h-1,2,3-triazolderivater som inhibitorer af fibrose - Google Patents
2h-1,2,3-triazolderivater som inhibitorer af fibrose Download PDFInfo
- Publication number
- DK3003038T3 DK3003038T3 DK14807059T DK14807059T DK3003038T3 DK 3003038 T3 DK3003038 T3 DK 3003038T3 DK 14807059 T DK14807059 T DK 14807059T DK 14807059 T DK14807059 T DK 14807059T DK 3003038 T3 DK3003038 T3 DK 3003038T3
- Authority
- DK
- Denmark
- Prior art keywords
- fibrose
- inhibitors
- triazold
- derivatives
- triazold derivatives
- Prior art date
Links
- 0 CCC(C)NI(=C)=C*Cc(nc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(c(ccc(C2CC2)c2)c2Cl)OC1 Chemical compound CCC(C)NI(=C)=C*Cc(nc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(c(ccc(C2CC2)c2)c2Cl)OC1 0.000 description 12
- CSWWLZIHWDOBBW-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC(CC1)COC1(C[n]1nccn1)c1cc(Cl)ccc1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC(CC1)COC1(C[n]1nccn1)c1cc(Cl)ccc1 CSWWLZIHWDOBBW-UHFFFAOYSA-N 0.000 description 1
- IGTXBBCIJVOAHQ-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CN2N=CC=C=CC2)(C(C)C)OC1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(CN2N=CC=C=CC2)(C(C)C)OC1 IGTXBBCIJVOAHQ-UHFFFAOYSA-N 0.000 description 1
- JLJRJROYXTUSTB-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CC2)OC1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CC2)OC1 JLJRJROYXTUSTB-UHFFFAOYSA-N 0.000 description 1
- MVCZVFITFGIFLB-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCC2)OC1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCC2)OC1 MVCZVFITFGIFLB-UHFFFAOYSA-N 0.000 description 1
- WPLVDSGIYZTOAR-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCNCC2)OC1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCNCC2)OC1 WPLVDSGIYZTOAR-UHFFFAOYSA-N 0.000 description 1
- HHPHXSRMJRFBSK-UHFFFAOYSA-N CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCOCC2)OC1 Chemical compound CCC(C)N(C1=O)N=CN1c(cc1)ccc1N(CC1)CCN1c(cc1)ccc1OCC1OC(C[n]2nccn2)(C2CCOCC2)OC1 HHPHXSRMJRFBSK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361832768P | 2013-06-07 | 2013-06-07 | |
PCT/US2014/041174 WO2014197738A1 (en) | 2013-06-07 | 2014-06-05 | Small molecule inhibitors of fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3003038T3 true DK3003038T3 (da) | 2019-11-11 |
Family
ID=52008597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14807059T DK3003038T3 (da) | 2013-06-07 | 2014-06-05 | 2h-1,2,3-triazolderivater som inhibitorer af fibrose |
Country Status (20)
Country | Link |
---|---|
US (2) | US9663499B2 (da) |
EP (2) | EP3626242A1 (da) |
JP (1) | JP6414831B2 (da) |
KR (1) | KR102240329B1 (da) |
CN (1) | CN105392364B (da) |
AU (1) | AU2014274830B2 (da) |
BR (1) | BR112015030203A2 (da) |
CA (1) | CA2913634C (da) |
CL (1) | CL2015003569A1 (da) |
DK (1) | DK3003038T3 (da) |
EA (1) | EA201592157A1 (da) |
ES (1) | ES2755125T3 (da) |
HK (1) | HK1221606A1 (da) |
MX (1) | MX2015016783A (da) |
PE (1) | PE20160523A1 (da) |
PL (1) | PL3003038T3 (da) |
PT (1) | PT3003038T (da) |
SG (1) | SG11201510011VA (da) |
TN (1) | TN2015000519A1 (da) |
WO (1) | WO2014197738A1 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ624963A (en) | 2009-04-29 | 2016-07-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
MY172372A (en) | 2009-06-15 | 2019-11-21 | Amarin Pharmaceuticals Ie Ltd | Compositions and methods for lowering triglycerides |
NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US9192609B2 (en) | 2013-04-17 | 2015-11-24 | Hedgepath Pharmaceuticals, Inc. | Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors |
AU2014274830B2 (en) | 2013-06-07 | 2017-11-09 | The California Institute For Biomedical Research | Small molecule inhibitors of fibrosis |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
WO2016094570A1 (en) * | 2014-12-10 | 2016-06-16 | The California Institute For Biomedical Research | Small molecule inhibitors of fibrosis |
IL243707A0 (en) | 2016-01-20 | 2016-05-01 | Galmed Res And Dev Ltd | Treatment to regulate the microbiota in the intestine |
US20190255143A1 (en) * | 2016-04-18 | 2019-08-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash) |
US11197870B2 (en) | 2016-11-10 | 2021-12-14 | Galmed Research And Development Ltd | Treatment for hepatic fibrosis |
CN106866459A (zh) * | 2017-03-30 | 2017-06-20 | 成都绿林科技有限公司 | 一种抗真菌药物中间体的制备方法 |
CN106986787A (zh) * | 2017-03-30 | 2017-07-28 | 成都绿林科技有限公司 | 一种泊沙康唑中间体的合成方法 |
US20190282565A1 (en) * | 2018-03-19 | 2019-09-19 | Gui-Bai Liang | Methods and Compositions for Treating Idiopathic Pulmonary Fibrosis |
KR102296068B1 (ko) | 2018-09-24 | 2021-09-02 | 애머린 파마슈티칼스 아일랜드 리미티드 | 대상체에서 심혈관 사건의 위험도를 감소시키는 방법 |
WO2020081446A1 (en) * | 2018-10-14 | 2020-04-23 | The University Of Chicago | Compositions and methods for activating nrf2-dependent gene expression |
WO2021207384A1 (en) * | 2020-04-07 | 2021-10-14 | Amarin Pharmaceuticals Ireland Limited | Methods of treating and/or preventing viral infections and/or diseases caused by viruses in a subject in need thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4218458A (en) * | 1978-06-23 | 1980-08-19 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
US4619931A (en) * | 1983-02-28 | 1986-10-28 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles |
US4791111A (en) | 1985-12-23 | 1988-12-13 | Janssen Pharmaceutica, N.V. | [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles having anti-microbial properties |
IL103558A0 (en) * | 1991-10-30 | 1993-03-15 | Schering Corp | Tri-substituted tetrahydrofuran antifungals |
CN1041425C (zh) | 1993-11-19 | 1998-12-30 | 国际壳牌研究有限公司 | 氧化稳定的聚酮聚合物组合物及其应用 |
US5521186A (en) | 1994-10-27 | 1996-05-28 | Janssen Pharmaceutica N.V. | Apolipoprotein-β synthesis inhibitors |
US5625064A (en) * | 1995-04-19 | 1997-04-29 | Schering Corporation | Process for the preparation of triazolones |
TW457240B (en) | 1995-04-20 | 2001-10-01 | Janssen Pharmaceutica Nv | Novel triazolones as apolipoprotein-B synthesis inhibitors |
EP0957101A1 (en) | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
DE60006541D1 (de) | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
EP1330448A2 (en) | 2000-06-20 | 2003-07-30 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders |
EP1511490A4 (en) * | 2002-05-31 | 2009-03-11 | Transform Pharmaceuticals Inc | NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS |
BRPI0820856A2 (pt) | 2007-12-13 | 2019-05-14 | Siena Bhiotech.S.P.A. | anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos |
WO2010021681A2 (en) | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US20110183948A1 (en) * | 2010-01-15 | 2011-07-28 | Infinity Pharmaceuticals, Inc. | Treatment of fibrotic conditions using hedgehog inhibitors |
GB201015079D0 (en) * | 2010-09-10 | 2010-10-27 | Helperby Therapeutics Ltd | Novel use |
WO2012047762A2 (en) | 2010-10-08 | 2012-04-12 | Amplyx Pharmaceuticals, Inc. | Antifungal agents |
DK2648726T3 (da) | 2010-12-07 | 2018-07-16 | Amira Pharmaceuticals Inc | Polycyklisk lpa1-antagonist og anvendelser deraf |
US9346791B2 (en) * | 2011-09-07 | 2016-05-24 | The Johns Hopkins University | Itraconazole analogs and use thereof |
AU2013208003B2 (en) | 2012-01-09 | 2017-12-14 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
JP6133431B2 (ja) | 2012-11-24 | 2017-05-24 | ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. | 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用 |
RS56606B1 (sr) | 2013-06-07 | 2018-02-28 | Rhizen Pharmaceuticals S A | Dvojno selektivni inhibitori pi3 kinaze delta i gama |
AU2014274830B2 (en) | 2013-06-07 | 2017-11-09 | The California Institute For Biomedical Research | Small molecule inhibitors of fibrosis |
-
2014
- 2014-06-05 AU AU2014274830A patent/AU2014274830B2/en active Active
- 2014-06-05 ES ES14807059T patent/ES2755125T3/es active Active
- 2014-06-05 WO PCT/US2014/041174 patent/WO2014197738A1/en active Application Filing
- 2014-06-05 TN TN2015000519A patent/TN2015000519A1/en unknown
- 2014-06-05 BR BR112015030203A patent/BR112015030203A2/pt not_active IP Right Cessation
- 2014-06-05 CN CN201480032411.7A patent/CN105392364B/zh active Active
- 2014-06-05 PE PE2015002576A patent/PE20160523A1/es not_active Application Discontinuation
- 2014-06-05 EP EP19191562.8A patent/EP3626242A1/en active Pending
- 2014-06-05 KR KR1020157036822A patent/KR102240329B1/ko active IP Right Grant
- 2014-06-05 PL PL14807059T patent/PL3003038T3/pl unknown
- 2014-06-05 EA EA201592157A patent/EA201592157A1/ru unknown
- 2014-06-05 MX MX2015016783A patent/MX2015016783A/es unknown
- 2014-06-05 CA CA2913634A patent/CA2913634C/en active Active
- 2014-06-05 SG SG11201510011VA patent/SG11201510011VA/en unknown
- 2014-06-05 JP JP2016518012A patent/JP6414831B2/ja active Active
- 2014-06-05 DK DK14807059T patent/DK3003038T3/da active
- 2014-06-05 EP EP14807059.2A patent/EP3003038B1/en active Active
- 2014-06-05 PT PT148070592T patent/PT3003038T/pt unknown
- 2014-06-05 US US14/895,813 patent/US9663499B2/en active Active
-
2015
- 2015-12-07 CL CL2015003569A patent/CL2015003569A1/es unknown
-
2016
- 2016-08-20 HK HK16109962.7A patent/HK1221606A1/zh unknown
-
2017
- 2017-04-14 US US15/488,206 patent/US9981956B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170217943A1 (en) | 2017-08-03 |
BR112015030203A2 (pt) | 2017-07-25 |
CA2913634A1 (en) | 2014-12-11 |
AU2014274830A1 (en) | 2015-11-26 |
KR20160029028A (ko) | 2016-03-14 |
EP3003038B1 (en) | 2019-08-14 |
AU2014274830B2 (en) | 2017-11-09 |
EP3003038A4 (en) | 2016-11-16 |
EP3626242A1 (en) | 2020-03-25 |
MX2015016783A (es) | 2016-07-18 |
JP6414831B2 (ja) | 2018-10-31 |
US9981956B2 (en) | 2018-05-29 |
CN105392364B (zh) | 2018-09-14 |
ES2755125T3 (es) | 2020-04-21 |
PT3003038T (pt) | 2019-11-19 |
US9663499B2 (en) | 2017-05-30 |
PL3003038T3 (pl) | 2020-02-28 |
EP3003038A1 (en) | 2016-04-13 |
CN105392364A (zh) | 2016-03-09 |
PE20160523A1 (es) | 2016-05-25 |
HK1221606A1 (zh) | 2017-06-09 |
EA201592157A1 (ru) | 2016-05-31 |
JP2016521710A (ja) | 2016-07-25 |
CA2913634C (en) | 2022-08-09 |
SG11201510011VA (en) | 2016-01-28 |
US20160130258A1 (en) | 2016-05-12 |
WO2014197738A1 (en) | 2014-12-11 |
TN2015000519A1 (en) | 2017-04-06 |
KR102240329B1 (ko) | 2021-04-14 |
CL2015003569A1 (es) | 2016-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3003038T3 (da) | 2h-1,2,3-triazolderivater som inhibitorer af fibrose | |
DK3442980T3 (da) | Heterocykliske forbindelser som ret-kinase-hæmmere | |
DK3371190T3 (da) | Heterocykliske forbindelser som pi3k-gamma-inhibitorer | |
DK3527263T3 (da) | Bipyrazolderivater som jak-inhibitorer | |
DK3298002T3 (da) | Heterocykliske amider som kinasehæmmere | |
DK3071203T3 (da) | Tetrahydroquinolinsammensætninger som bet-bromdomæne-inhibitorer | |
DK3077374T3 (da) | Pyrrolidinoner som herbicider | |
DK3019496T3 (da) | Pyrimidinderivater som kinaseinhibitorer | |
DK3066085T3 (da) | Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor | |
CL2016000257A1 (es) | Composiciones edulcorantes. | |
DK3357919T3 (da) | Aromatiske heterocykliske forbindelser som antiinflammatoriske forbindelser | |
DK3342771T3 (da) | Heterocykliske amider som kinaseinhibitorer | |
BR112017027339A2 (pt) | derivados de piperidina 1,4-substituída | |
DK3466949T3 (da) | Tricyklisk forbindelse som anticancermidler | |
FR3006466B3 (fr) | . | |
CL2016000258A1 (es) | Composiciones edulcorantes. | |
DK3094631T3 (da) | Pyrimidinyloxybenzenderivater som herbicider | |
DK3313832T3 (da) | 3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere | |
BR112016010220A2 (pt) | compostos inibidores de autoxatina. | |
DK2981535T3 (da) | Urinstofderivater, der er anvendelige som kinaseinhibitorer | |
DK2986726T3 (da) | Hidtil ukendte bacillusstammesammensætninger | |
DK3054936T5 (da) | 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer | |
DK3013796T3 (da) | Biarylderivater som gpr120-agonister | |
DK3544981T3 (da) | Benzodiazoliumforbindelser som enac-inhibitorer | |
DK2975030T3 (da) | Dihydropyridazin-3,5-dion-derivat |